Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Open-market sale Chief Financial Officer sold 5,000 shares at an average $37.56 ($187,797)
  2. 4 Open-market sale SVP, General Counsel sold 10,000 shares at $39.00 ($390,000)
  3. 4 Open-market sale SVP, General Counsel sold 10,000 shares at $34.00 ($340,000)
  4. 4 Open-market sale Chief Financial Officer sold 5,000 shares at $30.00 ($150,000)
  5. 4 Open-market sale President and CEO sold 10,000 shares at $29.55 ($295,500)
  6. 4 Open-market sale SVP, Technical Operations sold 25,000 shares at $33.00 ($825,000)
  7. 4 Exercise or conversion Chief Financial Officer acquired 60,000 shares (option exercise)
  8. 4 Open-market sale Chief Financial Officer sold 5,000 shares at $30.00 ($150,000)
  9. 4 Open-market sale President and CEO sold 10,000 shares at $26.56 ($265,600)
  10. 4 Open-market sale President and CEO sold 10,000 shares at $27.33 ($273,300)
  11. 4 Open-market sale Chief Financial Officer sold 5,000 shares at $30.16 ($150,800)
  12. 4 Exercise or conversion President and CEO acquired 150,000 shares (option exercise)
  13. 4 Exercise or conversion Chief Financial Officer acquired 30,000 shares (option exercise)
  14. 4 Grant or award SVP, General Counsel acquired 1,141 shares (grant or award)
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market sale SVP, Technical Operations sold 30,000 shares at $33.03 ($990,900)

Page 16 of 22 · 435 filings